Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

Infliximab ELISA Kit

Human, Maus und Ratte Infliximab ELISA-Kit Colorimetric-Assay zur Quantifizierung von Human, Maus und Ratte Infliximab.
Produktnummer ABIN4886393

Kurzübersicht für Infliximab ELISA Kit (ABIN4886393)

Target

Alle Infliximab Produkte
Infliximab

Reaktivität

  • 1
  • 1
  • 1
  • 1
Human, Maus, Ratte

Nachweismethode

Colorimetric

Methodentyp

Sandwich ELISA

Detektionsbereich

0.78-25 ng/mL

Applikation

ELISA

Proben

Plasma, Serum
  • Untere Nachweisgrenze

    0.78 ng/mL

    Verwendungszweck

    Quantification of Infliximab in biological matrices

    Analytische Methode

    Quantitative

    Spezifität

    Infliximab (Remicade)

    Kreuzreaktivität (Details)

    hIgG1 and Infliximab prepared at 250 ng/ mL were assayed and exhibited no cross-reactivity or interference.

    Bestandteile

    Coated microtiter plate, 96 wells
    Calibrator diluent. - 1.8ml
    Calibrator 12ul
    10X wash buffer - 25ml
    Assay buffer - 50ml
    1000X detection reagent - 17ul
    TMB - 12ml
    TMB stop solution - 12ml
    Plate sealers - 3

    Benötigtes Material

    Precision pipettes calibrated to deliver 5-1000μL
    Multi-channel pipette calibrated to deliver 50-200μL
    Plate shaker
    Disposable tips
    Vortex-Mixer
    Distilled or de-ionized water
    Microplate reader capable of reading 450nm with background subtrac
  • Applikationshinweise

    Optimal working dilution should be determined by the investigator.

    Probenmenge

    15 μL

    Testdauer

    2.5 h

    Plattentyp

    Pre-coated

    Protokoll

    The Infliximab ELISA kit is designed to measure free Infliximab with high specificity and sensitivity . This assay employs the sandwich enzyme immunoassay technique. A precoated anti-Infliximab 96 well plate is provided. Calibrator, quality control samples and test samples are pipetted into the appropriate wells. Infliximab present in biological matrices is bound by the immobilized capture antibody. After washing away any unbound substances, enzyme linked detection antibody is added to the wells. The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development. The color development is proportional to the amount of Infliximab present in test samples and the concentration is calculated from the standard series.

    Aufbereitung der Reagenzien

    Prepare the appropriate amount of required reagent on the day of use. Store all reagents as per instructions stated on the label. 1. Wash Buffer (1X) Preparation: Dilute wash buffer concentrate with ultra-pure water 1/10 before use (for example add 20 mL concentrate to 180 mL ultra-pure water). Mix well. 2. Detection Reagent (1X) Preparation: Dilute detection reagent with assay buffer 1/1000 before use (for example add 11 μL concentrate to 11 mL of assay buffer). Mix well. 3. Preparation of Calibrators: Prepare calibrators with concentrations ranging from 2,500 ng/mL to 78 ng/ mL. The following is an example calibrator curve.

    Probennahme

    This kit is compatible with EDTA-plasma, heparinplasma and serum samples. Samples can be stored at or below -20 °C for up to 1 year.

    Aufbereitung der Proben

    Dilute calibrators and test samples 1/100 with assay buffer (for example add 5μL of prepared calibrator or sample to 495μL of assay buffer). Mix well. *Note that test samples may require further dilution when peak values are predicted to exceed 2.5 μg/mL.

    Testdurchführung

    This assay employs the sandwich enzyme immunoassay technique. Anti- Infliximab is coated onto a 96 well microplate. Calibrator, quality control samples (if desired) and test samples are pipetted into the appropriate wells. Infliximab present in biological matrices is bound by the immobilized anti- Infliximab antibody. After washing away any unbound substances, enzyme linked anti- Infliximab antibody is added to the wells. This antibody is developed and purified specifically against truncated Remicade® (domain residing in Fc portion of the Remicade® molecule). The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development. The color development is proportional to the amount of Infliximab present in test samples. The color development is stopped and the intensity of the color is measured.

    Ergebnisberechnung

    1. Construct a standard curve by plotting the absorbance obtained from each standard against concentration. Use a 4 or 5 parameter curve fit. Alternatively a log-log curve fit may be used. 2. The concentration of the unknowns can be read directly from this standard curve using the absorbance value for each sample. 3. Any sample undiluted or diluted still reading greater than the highest standard should be diluted appropriately with calibrator diluent and retested. If the samples have been diluted, the concentration determined from the standard curve must be multiplied by the dilution factor.

    Testpräzision

    Precision: The precision was determined by analyzing samples prepared at 1000 ng/mL in 6 replicates on 6 different occasions. Intra-assay coefficient of variation (CV) < 10%. Inter-assay CV < 10%.

    Recovery: 1000 ng/mL of Infliximab was spiked in 10 lots of human serum. Recovery ranges are from 93-109% with an average recovery of 97%.

    Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Konservierungsmittel

    Without preservative

    Vorsichtsmaßnahmen

    Read manual completely before beginning

    Lagerung

    -20 °C

    Informationen zur Lagerung

    Store kit components at -20°C unless specified otherwise. DO NOT USE past kit expiration date. Some vials contain a small amount of reagents. Spin tubes on pulse setting prior to opening.

    Haltbarkeit

    12 months
  • Target Alle Infliximab Produkte

    Infliximab

    Substanzklasse

    Antibody

    Hintergrund

    Infliximab (Remicade®) is a chimeric monoclonal antibody against tumour necrosis factor alpha (TNF- α). Infliximab neutralizes the biological activity of TNF- α by binding with high affinity to the soluble (free floating in the blood) and transmembrane (located on the outer membranes of T cells and similar immune cells) forms of TNF-α, and inhibits or prevents the effective binding of TNF-α with its receptors.

    Gen-ID

    7124
Sie sind hier:
Chat with us!